Disclosure hits industry
July 16, 2013
THE Australian pharmaceutical
industry continues to face
significant headwinds, with a
new report from consulting firm
PricewaterhouseCoopers revealing
the ongoing impact of PBS reforms
and price disclosure.
Conducted in conjunction with
Medicines Australia, the Issues and
Decisions report is the outcome of a
confidential survey of a wide crosssection
of industry participants.
The study highlights a range of
issues, including the fact that about
a third of suppliers are considering
direct-to-pharmacy distribution.
Price disclosure is also predicted
to hurt pharmaceutical wholesalers,
with the report saying the more
competitive environment is likely
to see wholesalers review which
services and products they offer.
“Similarly, community pharmacy
will be required to examine new
business strategies and revenue
streams to counter the loss of
revenue from PBS items.
“As the government pays less
and patients pay the same for
medicines, it is pharmacy that
will suffer reduced margins and
profitability,” the report warns.
The full PwC report is available for
download by CLICKING HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Jul 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Jul 13
